IBD Evidence

Članek

Kaj povzroča KVČB? Genetika, okolje, naraščajoča pojavnost

Posodobljeno 4 min branje 60 navajanja

Žični endoskopski zanko, uporabljen za polipektomijo zgornjega prebavil in debelega črevesa
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Niti genetika niti okolje sama zase ne pojasnita vnetne črevesne bolezni (VČB). Genetika pove, kdo je dovzeten; epidemiologija pa pove, da sama dovzetnost ne more biti celotna zgodba, saj se je svetovni zemljevid bolezni spremenil prehitro, da bi to lahko pojasnili geni.

Kaj genetika dejansko kaže

Študije povezav na ravni celotnega genoma so opredelile znatno število lokusov, povezanih z dovzetnostjo za VČB. Metaanaliza podatkov o povezavah je opredelila 38 lokusov dovzetnosti in izpostavila genetsko tveganje, ki je skupno različnim populacijam, opazno pa je delno skupno tudi z drugimi imunsko pogojenimi boleznimi [25]. Ločena študija povezav na ravni celotnega genoma je posebej pokazala na imunsko aktivacijo več genov za integrine [24] — mehanistično zanimiv rezultat, saj zdravila, ki blokirajo integrine (razred antiintegrinskih bioloških zdravil, obravnavan na naši strani o zdravljenju), delujejo tako, da prekinejo prav tisto pot prehajanja levkocitov, v kateri sodelujejo ti geni.

Praktični zaključek genetike je ožji, kot bi ljudje pričakovali. VČB ni enogenska, mendelsko dedna bolezen — je poligenska, pri čemer vsak od številnih lokusov prispeva le majhen delež tveganja. Bližnji sorodnik (v prvem kolenu) z VČB poveča tveganje nad splošno populacijo, vendar velika večina ljudi, ki nosijo z VČB povezane genetske različice, bolezni nikoli ne razvije. Genetika postavi prag dovzetnosti; nekaj drugega odloči, ali je ta prag presežen.

Zakaj genetika ne more biti celotna zgodba

Genetska zgradba populacije se v nekaj desetletjih ne spremeni. Svetovna incidenca VČB pa se je. Analiza iz leta 2025, objavljena v reviji Nature, sledi incidenci VČB skozi tisto, kar poimenuje epidemiološke stopnje — nizka incidenca, faza pospeška, ko incidenca strmo naraste, nato pa faza ravnovesja sestave prevalence, v kateri se incidenca izravna, število ljudi, ki živijo z boleznijo, pa še naprej narašča, ker gre za kronično bolezen [35]. Regije, ki se danes na novo industrializirajo, prehajajo skozi fazo pospeška, skozi katero sta zahodna Evropa in Severna Amerika šli v dvajsetem stoletju.

Ta vzorec je bil dokumentiran že prej v sistematičnem pregledu populacijskih študij o svetovni incidenci in prevalenci [23], nadaljnji pregled, ki se posebej ukvarja z epidemiologijo po starostnih skupinah v dobi naprednih terapij, pa umešča trenutno globalno sliko [33]. Sistematični pregled, osredotočen na VČB z začetkom v otroštvu, je enak pospešujoč trend odkril posebej pri otrocih in mladostnikih [15], trende hospitalizacij v istem obdobju pa je opisal nadaljnji sistematični pregled s časovnimi analizami [7].

Geografski in časovni vzorec, ki sledi industrializaciji in ne genetskemu zdrsu, je najmočnejši razpoložljivi argument, da pomemben del vzročnega dela opravlja nekaj v načinu življenja populacije — ne le v tem, kako se rodi.

Okoljski kandidati

Krovni pregled metaanaliz je neposredno preučil okoljske dejavnike tveganja za VČB in združil dokaze iz številnih posameznih študij izpostavljenosti v eno samo sintezo [20]. Pošten povzetek te literature je, da ima več kandidatov podporne dokaze različne moči, noben pa se ni izkazal za zadosten sam po sebi — kar je skladno z boleznijo, ki verjetno zahteva, da genetsko dovzeten posameznik naleti na določeno kombinacijo izpostavljenosti.

Ena stvar, ki jo imamo: kako se deli sestavljajo

Kategorija dejavnikaKaj je utrjenoKaj ni
Genetska dovzetnostOpredeljenih na desetine prispevajočih lokusov; tveganje se kopiči v družinah in si deli mehanizme z drugimi imunskimi boleznimiNoben posamezen gen ni nujen ali zadosten; večina genetsko dovzetnih ljudi VČB nikoli ne razvije
Geografski/časovni vzorecIncidenca strmo naraste, ko se regije industrializirajo, nato se izravna, medtem ko prevalenca še naprej naraščaVzorec kaže, da je okolje pomembno; sam po sebi pa ne opredeli, katera izpostavljenost je najpomembnejša
Posamezne okoljske izpostavljenostiKrovni pregled je združil literaturo o izpostavljenosti za številne kandidatne dejavnikeNoben posamezen okoljski dejavnik ni potrjen kot nujen ali sam po sebi zadosten
Medsebojno delovanjeVerjetno in skladno s splošnim vzorcem podatkov: dovzetnost plus izpostavljenostS trenutnimi zasnovami študij na ravni posameznika ni neposredno merljivo

Zakaj je to praktično pomembno

Nič od tega ne spremeni obravnave. Ne opredeli živila, ki se mu je treba izogibati, spremembe življenjskega sloga, ki bi zagotovo preprečila poslabšanja, niti testa, ki bi z uporabno natančnostjo napovedal individualno tveganje. Kar pa pojasni, sta dve stvari, o katerih so bolniki pogosto neusklajeno obveščeni: da VČB v nobenem preprostem smislu ni „povzročena“ s prehrano ali stresom (genetika in okoljske spremembe na ravni populacije opravijo veliko večji del vzročnega dela kot vsakodnevne izbire) in da tudi ni zgolj genetska smola (naraščajoča incidenca v na novo industrializiranih regijah to samo po sebi izključuje). Oba ta preokvirjenja praviloma zmanjšata občutek krivde, ki ga bolniki poročajo ob vprašanju „kaj sem storil, da sem to povzročil“ — vprašanju, ki ga dokazna baza pravzaprav ne podpira za nobeno posamezno vedenje.

Pogosta vprašanja

Je VČB dedna? Bodo moji otroci zboleli?
Tveganje je povečano pri bližnjih sorodnikih (v prvem kolenu) osebe z VČB, vendar velika večina sorodnikov bolezni nikoli ne razvije. Gre za vzorec genov dovzetnosti, ne za mendelsko dedno bolezen.
Ali je mojo VČB povzročilo nekaj, kar sem jedel ali počel?
Noben posamezen prehranski ali življenjski dejavnik ni bil potrjen kot zadosten vzrok. Dokazi kažejo na kombinacijo genetske dovzetnosti in okoljskih izpostavljenosti na ravni populacije, ki se odvija skozi leta, ne pa na prepoznaven posamezni sprožilec.
Zakaj VČB postaja pogostejša v državah, kjer je bila nekoč redka?
To dovolj tesno sledi industrializaciji, da je eden najmočnejših argumentov za okoljsko sestavino — geni se ne spreminjajo dovolj hitro, da bi to pojasnili, vzorec pa je zdaj dokumentiran v več regijah in časovnih obdobjih.
Če genetika pojasni le dovzetnost, kaj je dejanski sprožilec?
Ni natančno ugotovljeno. Možni okoljski dejavniki so bili povzeti v dokazih krovnega pregleda, vendar se ni izkazalo, da bi bil kateri koli posamezen dejavnik nujen ali zadosten — to ostaja odprto raziskovalno področje in ne rešeno vprašanje.
Tri kamerne kapsule, uporabljene za slikanje požiralnika, tankega črevesa in debelega črevesa
Zaužite kapsule fotografirajo odseke tankega črevesa, do katerih običajni endoskop ne seže. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons

Sorodno branje

Dokazi za to stran Stolpčni graf, ki prikazuje sestavo 30 publikacij, navedenih na tej strani, po vrsti študije. 2563meta-analysis (25)randomised trial (6)review (3)other (1)
35 publikacij, 2015–2026. To je mešanica tako poskusov kot sintez, iz katere je trditev o vzroku razumna. Vir: seznam citatov te strani, spodaj.

Reference

Vsaka navedba spodaj povezuje na izvirni recenzirani zapis na PubMedu ali preko DOI. Nič tukaj ni nadomestilo za medicinski nasvet.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Mediterranean diet in treatment of inflammatory bowel disease: A systematic review and meta-analysis Singh A, Rana U, Chandnani S, et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026 · Meta-analysis DOIPubMed 41803562
  3. Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study Gregersen L, Moos C, Hikmat Z, et al. · Advances in nutrition (Bethesda, Md.) · 2026 · Systematic review DOIPubMed 41825595Full text
  4. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  5. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  6. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  7. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  8. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  9. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. Pre-Illness Index-Based Dietary Patterns and Inflammatory Bowel Disease Risk: A Systematic Review and Meta-Analysis Meng F, Zhang T, Meng X, et al. · Nutrition reviews · 2025 · Meta-analysis DOIPubMed 40700526
  12. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  13. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials Kuźmin L, Kubiak K, Lange E · Nutrients · 2025 · Systematic review DOIPubMed 40573159Full text
  14. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  15. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  16. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  17. Efficacy of different dietary therapy strategies in active pediatric Crohn's disease: a systematic review and network meta-analysis Ma J, Chong J, Qiu Z, et al. · PeerJ · 2024 · Meta-analysis DOIPubMed 39686992Full text
  18. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  19. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  20. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  21. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  22. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  23. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  24. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  25. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  26. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  27. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  28. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  29. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  30. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  31. Systematic Review of the Effects of Oat Intake on Gastrointestinal Health Valido E, Stoyanov J, Bertolo A, et al. · The Journal of nutrition · 2021 · Systematic review DOIPubMed 34486656
  32. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  33. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  34. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  35. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  36. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  37. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  38. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  39. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  40. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  41. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419
  42. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  43. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  44. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis Zhou XL, Xu W, Tang XX, et al. · BMC gastroenterology · 2014 · Meta-analysis DOIPubMed 25002150Full text
  45. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial Wellens J, Vanderstappen J, Hoekx S, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Randomised controlled trial DOIPubMed 40816342
  46. A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease Yap JM, Wall CL, Meredith-Jones K, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 41829955Full text
  47. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study Minato I, Mena P, Ricciardiello L, et al. · Molecular nutrition & food research · 2025 · Randomised controlled trial DOIPubMed 40255128Full text
  48. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study Delgarm P, Mokhtare M, Ebrahimi Daryani N, et al. · Scientific reports · 2025 · Randomised controlled trial DOIPubMed 41315628Full text
  49. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  50. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial Pasta A, Formisano E, Calabrese F, et al. · European journal of clinical investigation · 2025 · Randomised controlled trial DOIPubMed 39853756
  51. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  52. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  53. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  54. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition Svolos V, Hansen R, Nichols B, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 30550821
  55. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  56. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  57. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  58. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  59. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  60. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text

Ta stran je bila samodejno prevedena iz angleščine. Navedbe in številke ostajajo nespremenjene. Preberite angleški izvirnik, če se kaj zdi nenavadno. Preberite angleški izvirnik